IBDEI1N1 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29454,1,5,0)
 ;;=5^707.10
 ;;^UTILITY(U,$J,358.3,29454,2)
 ;;=^322142
 ;;^UTILITY(U,$J,358.3,29455,0)
 ;;=414.01^^186^1872^35
 ;;^UTILITY(U,$J,358.3,29455,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29455,1,4,0)
 ;;=4^Cor Atheroscl Natv C Vsl
 ;;^UTILITY(U,$J,358.3,29455,1,5,0)
 ;;=5^414.01
 ;;^UTILITY(U,$J,358.3,29455,2)
 ;;=^303281
 ;;^UTILITY(U,$J,358.3,29456,0)
 ;;=446.5^^186^1872^44
 ;;^UTILITY(U,$J,358.3,29456,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29456,1,4,0)
 ;;=4^Giant Cell Arteritis
 ;;^UTILITY(U,$J,358.3,29456,1,5,0)
 ;;=5^446.5
 ;;^UTILITY(U,$J,358.3,29456,2)
 ;;=^117658
 ;;^UTILITY(U,$J,358.3,29457,0)
 ;;=446.21^^186^1872^45
 ;;^UTILITY(U,$J,358.3,29457,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29457,1,4,0)
 ;;=4^Goodpasture's Syndrome
 ;;^UTILITY(U,$J,358.3,29457,1,5,0)
 ;;=5^446.21
 ;;^UTILITY(U,$J,358.3,29457,2)
 ;;=^52601
 ;;^UTILITY(U,$J,358.3,29458,0)
 ;;=V58.67^^186^1872^53
 ;;^UTILITY(U,$J,358.3,29458,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29458,1,4,0)
 ;;=4^Long-Term Use of Insulin
 ;;^UTILITY(U,$J,358.3,29458,1,5,0)
 ;;=5^V58.67
 ;;^UTILITY(U,$J,358.3,29458,2)
 ;;=^331585
 ;;^UTILITY(U,$J,358.3,29459,0)
 ;;=446.1^^186^1872^57
 ;;^UTILITY(U,$J,358.3,29459,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29459,1,4,0)
 ;;=4^Mucocutan Lymph Node Syndrome
 ;;^UTILITY(U,$J,358.3,29459,1,5,0)
 ;;=5^446.1
 ;;^UTILITY(U,$J,358.3,29459,2)
 ;;=^79494
 ;;^UTILITY(U,$J,358.3,29460,0)
 ;;=433.30^^186^1872^60
 ;;^UTILITY(U,$J,358.3,29460,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29460,1,4,0)
 ;;=4^Occl/Sten Mult/Bil Art w/o CRB
 ;;^UTILITY(U,$J,358.3,29460,1,5,0)
 ;;=5^433.30
 ;;^UTILITY(U,$J,358.3,29460,2)
 ;;=^295803
 ;;^UTILITY(U,$J,358.3,29461,0)
 ;;=451.83^^186^1872^66
 ;;^UTILITY(U,$J,358.3,29461,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29461,1,4,0)
 ;;=4^Phl/Thrombophl Deep Veins,Upper Extrem
 ;;^UTILITY(U,$J,358.3,29461,1,5,0)
 ;;=5^451.83
 ;;^UTILITY(U,$J,358.3,29461,2)
 ;;=^295745
 ;;^UTILITY(U,$J,358.3,29462,0)
 ;;=451.82^^186^1872^67
 ;;^UTILITY(U,$J,358.3,29462,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29462,1,4,0)
 ;;=4^Phl/Thrombophl Sup Veins,Upper Extrem
 ;;^UTILITY(U,$J,358.3,29462,1,5,0)
 ;;=5^451.82
 ;;^UTILITY(U,$J,358.3,29462,2)
 ;;=^295744
 ;;^UTILITY(U,$J,358.3,29463,0)
 ;;=451.84^^186^1872^68
 ;;^UTILITY(U,$J,358.3,29463,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29463,1,4,0)
 ;;=4^Phl/Thrombophl,Upper Extrem,Unspec
 ;;^UTILITY(U,$J,358.3,29463,1,5,0)
 ;;=5^451.84
 ;;^UTILITY(U,$J,358.3,29463,2)
 ;;=^295746
 ;;^UTILITY(U,$J,358.3,29464,0)
 ;;=446.0^^186^1872^70
 ;;^UTILITY(U,$J,358.3,29464,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29464,1,4,0)
 ;;=4^Polyartertitis Nodosa
 ;;^UTILITY(U,$J,358.3,29464,1,5,0)
 ;;=5^446.0
 ;;^UTILITY(U,$J,358.3,29464,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,29465,0)
 ;;=V81.0^^186^1872^75
 ;;^UTILITY(U,$J,358.3,29465,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29465,1,4,0)
 ;;=4^Screen for Ischemic Heart Disease
 ;;^UTILITY(U,$J,358.3,29465,1,5,0)
 ;;=5^V81.0
 ;;^UTILITY(U,$J,358.3,29465,2)
 ;;=^295687
 ;;^UTILITY(U,$J,358.3,29466,0)
 ;;=353.0^^186^1872^81
 ;;^UTILITY(U,$J,358.3,29466,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29466,1,4,0)
 ;;=4^Thoracic Outlet Syndrome
 ;;^UTILITY(U,$J,358.3,29466,1,5,0)
 ;;=5^353.0
 ;;^UTILITY(U,$J,358.3,29466,2)
 ;;=^16605
 ;;^UTILITY(U,$J,358.3,29467,0)
 ;;=451.89^^186^1872^84
 ;;^UTILITY(U,$J,358.3,29467,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,29467,1,4,0)
 ;;=4^Thrombophlebitis NEC
 ;;^UTILITY(U,$J,358.3,29467,1,5,0)
 ;;=5^451.89
 ;;^UTILITY(U,$J,358.3,29467,2)
 ;;=^176957
